Benzinga

España
Italia
대한민국
日本
Français
Benzinga Edge
Benzinga Research
Benzinga Pro

  • Get Benzinga Pro
  • Data & APIs
  • Events
  • Premarket
  • Advertise
Contribute
España
Italia
대한민국
日本
Français

Benzinga

  • Premium Services
  • Financial News
    Latest
    Earnings
    Guidance
    Dividends
    M&A
    Buybacks
    Interviews
    Management
    Offerings
    IPOs
    Insider Trades
    Biotech/FDA
    Politics
    Healthcare
    Small-Cap
  • Markets
    Pre-Market
    After Hours
    Movers
    ETFs
    Options
    Cryptocurrency
    Commodities
    Bonds
    Futures
    Mining
    Real Estate
    Volatility
  • Ratings
    Analyst Color
    Downgrades
    Upgrades
    Initiations
    Price Target
  • Investing Ideas
    Trade Ideas
    Long Ideas
    Short Ideas
    Technicals
    Analyst Ratings
    Analyst Color
    Latest Rumors
    Whisper Index
    Stock of the Day
    Best Stocks & ETFs
    Best Penny Stocks
    Best S&P 500 ETFs
    Best Swing Trade Stocks
    Best Blue Chip Stocks
    Best High-Volume Penny Stocks
    Best Small Cap ETFs
    Best Stocks to Day Trade
    Best REITs
  • Money
    Investing
    Cryptocurrency
    Mortgage
    Insurance
    Yield
    Personal Finance
    Forex
    Startup Investing
    Real Estate Investing
    Prop Trading
    Credit Cards
    Stock Brokers
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
Unusual Options Activity Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Screeners
Stock Screener
Top Momentum Stocks
Top Quality Stocks
Top Value Stocks
Top Growth Stocks
Compare Best Stocks
Best Momentum Stocks
Best Quality Stocks
Best Value Stocks
Best Growth Stocks
Connect With Us
facebookinstagramlinkedintwitteryoutubeblueskymastodon
About Benzinga
  • About Us
  • Careers
  • Advertise
  • Contact Us
Market Resources
  • Advanced Stock Screener Tools
  • Options Trading Chain Analysis
  • Comprehensive Earnings Calendar
  • Dividend Investor Calendar and Alerts
  • Economic Calendar and Market Events
  • IPO Calendar and New Listings
  • Market Outlook and Analysis
  • Wall Street Analyst Ratings and Targets
Trading Tools & Education
  • Benzinga Pro Trading Platform
  • Options Trading Strategies and News
  • Stock Market Trading Ideas and Analysis
  • Technical Analysis Charts and Indicators
  • Fundamental Analysis and Valuation
  • Day Trading Guides and Strategies
  • Live Investor Events
  • Pre-market Stock Analysis and News
  • Cryptocurrency Market Analysis and News
Ring the Bell

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.

  • Terms & Conditions
  • Do Not Sell My Personal Data/Privacy Policy
  • Disclaimer
  • Service Status
  • Sitemap
© 2026 Benzinga | All Rights Reserved
March 6, 2024 1:21 PM 2 min read

Spanish Healthcare Firm Grifols Hit With New Gotham City's Short Report, Faces Questions Regarding Transparency, Integrity, Ethical Conduct

by Vandana Singh Benzinga Editor
Follow
GRFS Logo
GRFSGrifols SA
$8.59-%
Overview

Grifols had previously denied Gotham City’s accusations, as per its February SEC filing, saying it had already replied to all of the questions raised in the latter’s reports.

Grifols claimed in its public February 20 response that the company had addressed all our questions, yet new information from the Kepler note suggests otherwise, the report added. 

According to the Kepler note, Grifols claims that €321 million (the Grifols 2022 financial statements indicate €319 million) of “other financial assets with related parties” refers to a “cash pooling financing arrangement” that Haema and BPC have with Scranton, but Gotham City says it is lending activity between Haema/BPC and Scranton.

Gotham said Grifols’ representation of the lending activity was “neither detailed nor correctly identifies the nature of the transactions.”

Gotham states, “On the one hand, Grifols publicly claimed (for all to see) that they have answered all our questions we asked on February 20; on the other hand, it appears that Grifols answered some of our questions by selectively disclosing new information to select analysts that same week, after the company had claimed that it had previously answered all our questions.”

In January, Gotham City Research released a short report on Grifols alleging that it manipulated its accounts to lower its leverage artificially.

The report alleges that Grifols included satellite companies’ earnings in its accounts but excluded their debts, distorting its actual leverage ratio. 

The European Central Bank initiated inquiries into several lenders, urging them to disclose their exposure to Grifols and its affiliated entities following accusations of financial manipulation.

In January, Grifols filed a lawsuit in a United States court against Daniel Yu, Gotham City Research’s founder, and his companies for the financial and reputational damages.

Price Action: GRFS shares are down 12.15 at $5.43 on the last check Wednesday.

Photo by evan_huang on Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.


Posted In:
BiotechNewsHealth CareMoversTrading IdeasGeneralBriefsStories That Matterwhy it's moving

Grifols SA (NASDAQ:GRFS) shares are down on Wednesday following the publication of a new report by Gotham City Research questioning the company’s “transparency, integrity and ethical conduct.”

GRFS Logo
GRFSGrifols SA
$8.59-%
Overview
Comments
Loading...